Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Fish and Richardson
Mallinckrodt
Johnson and Johnson
Deloitte
US Army
Citi
Cantor Fitzgerald
Federal Trade Commission
Queensland Health

Generated: December 10, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,754,731

« Back to Dashboard

Which drugs does patent 7,754,731 protect, and when does it expire?


Patent 7,754,731 protects ISENTRESS, DUTREBIS, and ISENTRESS HD, and is included in four NDAs. There has been one Paragraph IV challenge on Isentress.

Protection for ISENTRESS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-one patent family members in thirty-three countries.

Summary for Patent: 7,754,731

Title:Potassium salt of an HIV integrase inhibitor
Abstract:Potassium salts of Compound A and methods for their preparation are disclosed, wherein Compound A is of formula: ##STR00001## Compound A is an HIV integrase inhibitor useful for treating or prophylaxis of HIV infection, for delaying the onset of AIDS, and for treating or prophylaxis of AIDS.
Inventor(s): Belyk; Kevin M. (Somerset, NJ), Morrison; Henry G. (Simi Valley, CA), Mahajan; Amar J. (Piscataway, NJ), Kumke; Daniel J. (Colts Neck, NJ), Tung; Hsien-Hsin (Edison, NJ), Wai; Lawrence (Scotch Plains, NJ), Pruzinsky; Vanessa (Metuchen, NJ)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:11/293,678
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process; Use; Composition; Compound; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Merck Sharp DohmeISENTRESSraltegravir potassiumPOWDER;ORAL205786-001Dec 20, 2013RXYesYes► Subscribe► Subscribe► SubscribeY
Merck Sharp DohmeISENTRESSraltegravir potassiumTABLET, CHEWABLE;ORAL203045-001Dec 21, 2011RXYesNo► Subscribe► Subscribe► SubscribeY
Merck Sharp DohmeISENTRESSraltegravir potassiumTABLET, CHEWABLE;ORAL203045-002Dec 21, 2011RXYesYes► Subscribe► Subscribe► SubscribeY
Merck Sharp DohmeDUTREBISlamivudine; raltegravir potassiumTABLET;ORAL206510-001Feb 6, 2015DISCNNoNo► Subscribe► Subscribe► SubscribeY
Merck Sharp DohmeISENTRESSraltegravir potassiumTABLET;ORAL022145-001Oct 12, 2007RXYesYes► Subscribe► Subscribe► SubscribeY
Merck Sharp DohmeISENTRESS HDraltegravir potassiumTABLET;ORAL022145-002May 26, 2017RXYesNo► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,754,731

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,357,798Process for preparing N-alkylated hydroxypyrimidinone compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,754,731

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2588398► Subscribe
China101068793► Subscribe
Costa Rica9146► Subscribe
Cyprus1112859► Subscribe
Denmark1819700► Subscribe
Eurasian Patent Organization200701204► Subscribe
Eurasian Patent Organization012418► Subscribe
European Patent Office1819683► Subscribe
European Patent Office1819700► Subscribe
Spain2370136► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Chinese Patent Office
Covington
Chubb
US Department of Justice
AstraZeneca
Johnson and Johnson
Baxter
Federal Trade Commission
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot